Proxy Results (Form 8-K)

On June 9, 2026, Design Therapeutics, Inc. (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 14, 2026, the record date for the Annual Meeting, 62,441,429 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Voting results are, where applicable, reported by rounding fractional share voting down to the nearest whole number.

Proposal 1. Election of Director

The Company's stockholders elected the one person listed below as a Class II director, to serve until the Company's 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or, if sooner, until his death, resignation or removal. The final voting results are as follows:

Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm

The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: